ESPERION Reports Preliminary Fourth Quarter 2020 Financial Results and Further Commits to Unmet Patient Needs with Oral PCSK9 Inhibitor Program
FirstWord Pharma,
– Fourth-quarter 2020 U.S. net product revenue estimated between $8.0 and $8.5 million – – Range represents over 140 percent…